Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

Blisibimod for B-Cell Mediated Autoimmune Disease

Discussion in 'Other Health News and Research' started by merylg, Dec 4, 2011.

  1. merylg

    merylg Senior Member

    Messages:
    824
    Likes:
    636
    Sydney, NSW, Australia
    http://www.bioportfolio.com/news/ar...nterim-B-cell-Analysis-Of-Pearl-sc-Study.html

    "About B-Cell Activating Factor (BAFF) and blisibimod

    BAFF has been associated with a wide range of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications."
     

See more popular forum discussions.

Share This Page